---

Postmenopausal Bleeding (PMB) — Investigation Algorithm

---

Epidemiology & Risk

• ~10% of women with PMB have endometrial or cervical malignancy
• 90% of endometrial cancers present with PMB — so PMB must always be taken seriously
• Endometrial cancer rates are rising; Black women have disproportionately higher incidence and mortality

• Obesity (BMI ≥30), diabetes, hypertension ("Corpus cancer triad")
• Nulliparity, late menopause
• Unopposed oestrogen (including tamoxifen use)
• Hereditary syndromes (Lynch syndrome)

---

Causes of PMB (Common → Less Common)

---

Investigation Algorithm

Step 1 — History & Clinical Assessment

• Characterise bleeding (amount, duration, frequency, recurrence)
• Full gynaecological history: LMP, parity, HRT use, tamoxifen, anticoagulants
• Risk factor assessment (BMI, diabetes, family history of Lynch syndrome)
• Red flags: recurrent bleeding, persistent bleeding, high-risk background

Step 2 — Examination

• Speculum examination — inspect vulva, vagina, cervix for:
  • Atrophic changes
  • Cervical polyps, ectropion, visible lesions
• Bimanual pelvic examination — uterine size/tenderness, adnexal masses

Step 3 — First-Line Investigations

⚠️ ACOG 2026 update (major change): ACOG now recommends both TVUS and endometrial tissue sampling as part of the initial evaluation for most patients — replacing the prior approach of using TVUS alone when ET ≤4 mm. This shift was driven by evidence that 5–12% of cancers may be missed using ultrasound alone as the triage tool. The combination approach is especially important for Black women.

---

TVUS Endometrial Thickness (ET) Interpretation

• 3 mm cut-off: sensitivity 97.9%, specificity 35.4%
• 4 mm cut-off: sensitivity 94.8%, specificity 46.7%
• 5 mm cut-off: sensitivity 90.3%, specificity 54%

---

TVUS Decision Pathway

PMB
  │
  ▼
Pelvic examination + Cervical cytology
  │
  ▼
Transvaginal Ultrasound (TVUS)
  │
  ├── ET ≤ 4 mm ──────────────────────────────┐
  │   (and uniform, no polyp/mass)             │
  │                                            ▼
  │                               No biopsy required
  │                               UNLESS: recurrent PMB / risk factors
  │                               → then proceed to hysteroscopy
  │
  ├── ET > 4 mm ──────────────────────────────┐
  │   (or irregular outline / polyp)           │
  │                                            ▼
  │                          Endometrial biopsy (Pipelle)
  │                          ± Hysteroscopy
  │
  └── ET not visualised ──────────────────────┐
                                              ▼
                                    Proceed to Hysteroscopy

---

Special Situations

HRT Users

Tamoxifen Users

• ET correlation is poor (subendometrial changes cause artifactual thickening)
• Any PMB on tamoxifen warrants full evaluation with hysteroscopy, regardless of ET

Recurrent PMB

• Investigate regardless of ET; hysteroscopy is often required even with thin endometrium

Uterine Fluid (Hydrometra / Haematometra)

• If ET >4 mm within the fluid, or fluid is echogenic → proceed to biopsy
• Thin ET within fluid (<4 mm): reassure if no other concerns, but monitor

Anticoagulant Users

• Procedures carry low risk; anticoagulation does not need to be stopped for Pipelle biopsy or outpatient hysteroscopy

Asymptomatic Thickened Endometrium (Incidental Finding)

• ET ≥11 mm: investigate regardless of symptoms
• ET 5–10 mm with risk factors: offer investigation

---

Step 4 — Hysteroscopy

• ET >4 mm (especially if irregular outline or focal lesion)
• Inadequate/failed Pipelle biopsy
• Recurrent PMB despite previous negative workup
• Tamoxifen use
• Suspected polyp / submucosal fibroid on USS
• Unable to visualise ET on TVUS

• Outpatient hysteroscopy — preferred; direct visualisation + targeted biopsy
• Inpatient hysteroscopy + D&C — for patients unable to tolerate outpatient procedure or where pathology is complex

---

Endometrial Biopsy Interpretation

---

Additional Investigations (Second Line / Targeted)

---

Referral Criteria (Urgent / Two-Week Wait)

• Any PMB requires urgent gynaecological assessment
• Visible cervical lesion → urgent colposcopy referral
• Confirmed or suspected malignancy → gynaecological oncology MDT

---

Key Sources

• Berek & Novak's Gynecology — Diagnosis & Management of Postmenopausal Abnormal Bleeding, Ch. 10
• ACOG Clinical Practice Update (April 2026) — recommends combined TVUS + biopsy for most patients with PMB
• NHS Lanarkshire / SIGN 61 guideline (2025) — ET ≤4 mm threshold; full guideline PDF
• RCOG Patient Information (2025) — RCOG PMB poster

---

Cervical Cancer Stage IA — Fertility-Sparing Treatment

---

FIGO 2018 Stage IA Definition

---

Prerequisites for Fertility-Sparing Approach

Assignment to favourable criteria requires all clinicopathological variables to be considered together.

---

Decision Algorithm by Sub-Stage

Stage IA1 (invasion ≤3 mm)

IA1, LVSI-Negative ✓ (most favourable)

Cervical conisation (cold knife cone or LEEP)
  │
  ├── Margins NEGATIVE
  │     │
  │     └── Conisation alone is sufficient — NO lymph node staging required
  │           ↓
  │         Follow-up (colposcopy + cytology every 6 months × 2 yrs, then annually)
  │
  └── Margins POSITIVE
        │
        └── Repeat excision (preferred) or proceed to simple trachelectomy

IA1, LVSI-Positive ✗ (higher risk)

Conisation + Pelvic lymph node evaluation
  │             (Sentinel lymph node [SLN] mapping preferred, or full PLND)
  │
  ├── Nodes NEGATIVE + Margins NEGATIVE
  │     └── Conservative management acceptable
  │
  └── Nodes POSITIVE
        └── Fertility-sparing surgery CONTRAINDICATED
              → Standard radical treatment required

---

Stage IA2 (invasion >3 mm to ≤5 mm)

Stage IA2 — Desire fertility preservation
  │
  ├── Conisation (cold knife) to establish/confirm pathology
  │     +
  │     Pelvic lymph node staging (SLN biopsy ± full PLND) — MANDATORY
  │
  ├── If margins negative + nodes negative + LVSI-negative:
  │     Option A: Conisation alone with close follow-up (ConCerv trial data)
  │     Option B: Simple trachelectomy (vaginal or abdominal)
  │
  ├── If margins positive or LVSI-positive:
  │     Radical trachelectomy + pelvic lymph node dissection
  │
  └── Nodes POSITIVE at any point:
        → Fertility-sparing surgery CONTRAINDICATED

---

Surgical Options: Detail

1. Conisation (Cold Knife Cone / LEEP)

---

2. Simple Trachelectomy (Non-Radical)

---

3. Radical Trachelectomy (with Parametrectomy)

⚠️ ESGO 2024 update: Radical trachelectomy (removal of parametria) is NOT recommended for stage IA2–IB1 tumours ≤2 cm meeting the ConCerv strict criteria (LVSI-negative, ≤10 mm invasion, negative margins/ECC). In these low-risk cases, simple trachelectomy or conisation + lymph node staging is preferred, as parametrial involvement is exceedingly rare.

---

4. Lymph Node Staging: When Is It Required?

---

Adjuvant / Additional Considerations

HRT/Ovarian Function

• Ovaries are preserved in fertility-sparing surgery
• For adenocarcinomas ≤IB1, ovarian metastasis risk is <2% — ovarian preservation is safe

HPV Adenocarcinoma (Silva Pattern)

• Pattern A: Most favourable — conisation alone often sufficient
• Pattern B (no LVSI): Acceptable for conservative management
• Pattern C: Higher risk — cautious; radical approach more often needed

Neoadjuvant Chemotherapy (NACT)

• For tumours 2–4 cm (IA2 not technically, but borderline IB) where trachelectomy is desired but tumour size is borderline
• Platinum-based regimens (cisplatin/paclitaxel) to downsize tumour
• After NACT response, conisation/trachelectomy + node staging may be feasible
• Data remain limited; only in specialised centres

---

Obstetric Outcomes After Fertility-Sparing Surgery

• Delivery is usually by elective caesarean section (due to cervical cerclage and absence of cervix)
• Cerclage should remain in place for all subsequent pregnancies

---

Follow-Up After Fertility-Sparing Surgery

---

Contraindications to Fertility-Sparing Surgery

• Positive pelvic lymph nodes
• Tumour at or involving the internal cervical orifice
• Tumour size >4 cm
• Distant metastases
• Non-HPV-associated adenocarcinoma (e.g. gastric-type, clear cell) — unfavourable histology
• Patient preference for definitive surgery

---

Summary Table

---

Key References

• ESGO/ESHRE/ESGE Guidelines (2024) — Lancet Oncology Nov 2024; Pocket Guide
• NCCN Clinical Practice Guidelines — Cervical Cancer 2026
• ConCerv Trial (Schmeler et al., 2021) — prospective evidence supporting conservative surgery in low-risk early cervical cancer
• Creasy & Resnik's Maternal-Fetal Medicine — fertility-sparing surgery in cervical cancer in pregnancy
• Meta-analysis: open vs. MIS radical trachelectomy [PMID 37838671]

---

Clinical Scenario: Stage IA1 Cervical Carcinoma Diagnosed on LLETZ — 30-Year-Old Nulliparous, Wishes to Conceive

The Answer

---

Reasoning: Why This Is Sufficient

FIGO Stage IA1 Defined

• Invasion ≤3 mm in depth (microscopic only — not visible to the naked eye)
• The LLETZ/LEEP has already excised the transformation zone containing the lesion

Key Decision Point: Margin Status + LVSI

• The LLETZ has effectively treated the lesion if margins are clear
• The parametrial invasion risk is negligible (<0.5%) at IA1 with no LVSI
• No further surgery, lymph node staging, or trachelectomy is required

---

Management Plan

Immediate

• Confirm negative margins on the LLETZ specimen histopathology (both endocervical and ectocervical margins free of carcinoma AND high-grade dysplasia/HSIL)
• Confirm absence of LVSI on histological review
• MRI pelvis is not routinely required for IA1 LVSI-negative, but may be done if margins are equivocal

Surveillance Protocol (ESGO 2024 / RCOG)

• No restriction on attempting to conceive — she may try to conceive immediately after adequate wound healing (typically 6–8 weeks after LLETZ)
• Advise regarding slightly increased risk of preterm labour and cervical insufficiency (due to prior LLETZ — though risk is lower with LLETZ than with cold knife cone)
• Cervical length monitoring in pregnancy (transvaginal USS at ~16 weeks) is prudent

If She Becomes Pregnant

• Manage as high-risk pregnancy (obstetric review)
• Increased surveillance for preterm birth
• Monitor for signs of recurrence at each obstetric visit

---

Why NOT Trachelectomy or Hysterectomy Here?

---

If Margins Are Positive (Contingency)

LLETZ margins positive for carcinoma or HSIL
        │
        ▼
 Repeat LEEP/cold knife cone (preferred)
        │
        ├── Achieves clear margins → Surveillance
        │
        └── Cannot clear margins → Simple trachelectomy
              (preserves uterus and fertility)

---

If LVSI Is Present (Contingency)

• Sentinel lymph node (SLN) mapping + biopsy is recommended
• If nodes negative → surveillance or simple trachelectomy acceptable
• If nodes positive → fertility-sparing surgery is contraindicated → chemoradiation

---

Summary Box

30-year-old nulliparous woman, Stage IA1 cervical carcinoma on LLETZ with clear margins and no LVSI:

✅ No further surgery required ✅ May attempt pregnancy without delay (after 6–8 weeks healing) ✅ Regular colposcopy/cytology surveillance every 6 months ⚠️ Counsel regarding small increased preterm birth risk from prior LLETZ ⚠️ Cervical length monitoring recommended during pregnancy

---

• ESGO/ESHRE/ESGE Fertility-Sparing Guidelines (Lancet Oncology, 2024)
• NCCN Clinical Practice Guidelines — Cervical Cancer 2026
• Goldman-Cecil Medicine — Cervical Cancer Treatment & Prognosis
• Schwartz's Principles of Surgery, 11th ed. — Table 41-8
• BC Cancer Colposcopy Guidelines — Microinvasive Cervical Cancer (Stage IA1) Management Algorithm